(Total Views: 307)
Posted On: 07/11/2019 12:57:12 PM
Post# of 149108
I just finished reading interesting article in
“ Cancer Therapy Advisor “
In advanced non-small cell lung cancer-NSCLC ,
They compare respond of treatment to immunotherapy and chemotherapy in men and women..
They use checkpoint inhibitors as immunotherapy.
Women benefit more from combination of checkpoint inhibitors plus chemotherapy ..
-women, have overall hazard ratio of ..0.48 ( 95%CI, 0.35-0.67)
-In men. overall hazard ratio of ............0.76 ( 95%CI, 0.66-0.87)
When they looked at monotherapy , either chemo or checkpoint inhibitors
Men did better in both
In either monotherapy.........
-Women hazard ratio ...0.97 (95%CI, 0.79-1.19)
-Men..Hazard ratio....... 0.78 ( 95%CI, 0.60-1.01)
Of course those results are hypothesis only at this point but I hope that our TNBC women will have superior results to combination of Carboplatin and Leronlimab ...
“ Cancer Therapy Advisor “
In advanced non-small cell lung cancer-NSCLC ,
They compare respond of treatment to immunotherapy and chemotherapy in men and women..
They use checkpoint inhibitors as immunotherapy.
Women benefit more from combination of checkpoint inhibitors plus chemotherapy ..
-women, have overall hazard ratio of ..0.48 ( 95%CI, 0.35-0.67)
-In men. overall hazard ratio of ............0.76 ( 95%CI, 0.66-0.87)
When they looked at monotherapy , either chemo or checkpoint inhibitors
Men did better in both
In either monotherapy.........
-Women hazard ratio ...0.97 (95%CI, 0.79-1.19)
-Men..Hazard ratio....... 0.78 ( 95%CI, 0.60-1.01)
Of course those results are hypothesis only at this point but I hope that our TNBC women will have superior results to combination of Carboplatin and Leronlimab ...
(0)
(0)Scroll down for more posts ▼
